Kaya17

Current & Future Products

Patients in physician’s offices, airports, schools, educational institutions, nursing homes, clinics, factories, and other essential industries are urgently in need of effective weekly, and sometimes daily testing. The only viable option is on-site diagnostic testing. KAYA17 has focused on creating an accurate, rapid test for COVID-19 to meet urgent national needs and has also got several products in the pipeline.

 

Urgent Point-of-care Need

For instance, in order to resume close to full capacity air travel, testing has to occur at mobile test kiosks at the airport. To prevent long wait times, testing should happen in parallel with wait times of no less than 30 minutes per traveler. Similar requirements exist if schools, factories and entertainment centers need to open.

Such a thorough output is possible only if there are testing kiosks at each gate of the airport. Only tests that are rapid and run on machines that are portable, compact, and low cost can be run in such kiosks. In order to test a plane with 300 people, multiple kiosks running parallel tests will have to be deployed to process all the travellers within one hour.

It is important that the tests be sensitive and specific with zero false negatives. Existing rapid tests are NOT sensitive and have high incidences of false negatives, hence they are unsuitable for testing at high traffic places like airports, schools, and entertainment centers.

But KAYA17 changes that because it combines accuracy with speed, convenience and portability!

 

The KAYA17 POCT Benefits and Potential

The KAYA17 point-of-care test is a 15-minute Rapid test for COVID-19, which is perfectly adaptable for testing individuals, as well as small or large groups of people. The testing may be done infrequently or on a regular periodic basis. It can also be done quickly, accurately, and inexpensively. KAYA17’s proprietary software makes the workflow, and the initial data gathering to electronic delivery of the final results simple in various testing scenarios.

Testing at Airports, Terminals and Stations

Rapid, accurate, inexpensive testing will save the industry billions.

Testing at Schools and Institutions

A saliva sample is convenient. A nasal swab is not, especially for the elderly and children.

Testing at Workspaces and Factories

KAYA17 is the only rapid test in the world that is also viable for pooling, hugely reducing costs.

FUTURE KAYA17 PRODUCTS BEYOND COVID-19

The KAYA17 platform technology has a wide range of applications. With a minor change to the reagents, rapid Point-of-care tests can be developed for other medical diagnostic targets. No change will be required for the cartridge and reader. This allows the technology to be used in the rapid diagnosis of several other diseases and conditions as well, with the same level of accuracy and efficiency.

Cervical Cancer : Test validated with patient samples @ All India Institute of Medical Sciences (AIIMS)
Food Diagnostics : Test validated for E.coli, salmonella, Listeria
Allergy Testing : Under development

OTHER TESTS : The KAYA17 technology base goes beyond COVID-19 testing, using the same platform. The following tests are candidates for future development

US Market : Hepatitis B, UTI, CancerMarkers, Cardiac Markers, Influenza A & B, Nora Virus, Strep, Staph, Sepsis
Indian Market : Cervical cancer, UTI, Hepatitis B & C, HIV, Food bacteria (E.coli, Salmonella, Listeria), Water testing, Dengue, Chikungunya

The Need for POCT Testing

Moving from centralized labs to testing in the doctor’s office or other testing locations with accurate, quick micro-level, local testing and results provided instantly to patients via a specially developed app provides system-wide benefits to the healthcare industry.

Immediate diagnosis

Quicker diagnosis and turnaround on tests, with greater number of tests

Reduced burden on healthcare

Saving time to response, while significantly increasing impact and efficiency

Reduced management burden

Overall simpler methods are more customizable and inexpensive